• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the First Half of 2019


The Center for Biosimilars® recaps the 5 most-read stories of 2019 to date.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

It’s been a busy year for biosimilars, and this week, we’re recapping the 5 most-read stories of 2019 to date.

Number 5: The year opened with price hikes to a number of prescription drugs.

Number 4: The FDA approved another biosimilar trastuzumab product referencing Herceptin.

Number 3: Biosimilar developer Pfizer confirmed that it had cut 5 preclinical biosimilar programs from its portfolio.

Number 2: The FDA released its long-awaited final guidance on demonstrating interchangeability.

Number 1: The FDA approved Samsung Bioepis’ trastuzumab biosimilar.

What will the second half of the year hold for biosimilars? Stay up to date with the key news as it unfolds at centerforbiosimilars.com.

Related Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Related Content
© 2024 MJH Life Sciences

All rights reserved.